Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in Multiple Myeloma After Autologous Hematopoietic Cell Transplant
NCT06523699Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recombinant human interleukin-7 in multiple myeloma (MM) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Rate of non-hematologic grade >=3 CYT107 treatment-related Adverse Events. Started Apr 2025; status: active, not recruiting.
02
Drugs
recombinant human interleukin-7
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06523699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523699.